Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.49
+2.06 (27.73%)
At close: Feb 24, 2026, 4:00 PM EST
9.30
-0.19 (-2.02%)
After-hours: Feb 24, 2026, 7:59 PM EST
Vir Biotechnology Employees
Vir Biotechnology had 408 employees as of December 31, 2024. The number of employees decreased by 179 or -30.49% compared to the previous year.
Employees
408
Change (1Y)
-179
Growth (1Y)
-30.49%
Revenue / Employee
$168,029
Profits / Employee
-$1,073,498
Market Cap
1.32B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 408 | -179 | -30.49% |
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Sep 30, 2021 | 395 | 98 | 33.00% |
| Jun 30, 2021 | 367 | 114 | 45.06% |
| Mar 31, 2021 | 340 | 103 | 43.46% |
| Dec 31, 2020 | 327 | 98 | 42.79% |
| Sep 30, 2020 | 297 | 80 | 36.87% |
| Jun 30, 2020 | 253 | 47 | 22.82% |
| Mar 31, 2020 | 237 | 31 | 15.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| EyePoint | 165 |
| Capricor Therapeutics | 160 |
| Zenas BioPharma | 130 |
| MoonLake Immunotherapeutics | 100 |
| Inventiva | 84 |
| Taysha Gene Therapies | 73 |
| Savara | 59 |
VIR News
- 5 hours ago - Vir Biotechnology Announces Proposed Public Offering of Common Stock - Business Wire
- 7 hours ago - Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish - Seeking Alpha
- 8 hours ago - These Analysts Boost Their Forecasts On Vir Biotechnology - Benzinga
- 17 hours ago - What's Happening With VIR Stock? - Forbes
- 19 hours ago - Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 1 day ago - Astellas collaborates with Vir to develop its experimental prostate cancer drug - Reuters
- 1 day ago - Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer - Business Wire